<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Hematol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann. Hematol</journal-id>
      <journal-title-group>
        <journal-title>Annals of Hematology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0939-5555</issn>
      <issn pub-type="epub">1432-0584</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24782121</article-id>
      <article-id pub-id-type="pmc">4119934</article-id>
      <article-id pub-id-type="publisher-id">2090</article-id>
      <article-id pub-id-type="doi">10.1007/s00277-014-2090-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Identification of acquired mutations by whole-genome sequencing in GATA-2 deficiency evolving into myelodysplasia and acute leukemia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Fujiwara</surname>
            <given-names>Tohru</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fukuhara</surname>
            <given-names>Noriko</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Funayama</surname>
            <given-names>Ryo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nariai</surname>
            <given-names>Naoki</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kamata</surname>
            <given-names>Mayumi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nagashima</surname>
            <given-names>Takeshi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kojima</surname>
            <given-names>Kaname</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Onishi</surname>
            <given-names>Yasushi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sasahara</surname>
            <given-names>Yoji</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ishizawa</surname>
            <given-names>Kenichi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nagasaki</surname>
            <given-names>Masao</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakayama</surname>
            <given-names>Keiko</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Harigae</surname>
            <given-names>Hideo</given-names>
          </name>
          <address>
            <phone>+81-22-717-7165</phone>
            <fax>+81-22-717-7497</fax>
            <email>harigae@med.tohoku.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Hematology and Rheumatology, Tohoku University Graduate School, 2-1 Seiryo-cho, Aoba-ku, Sendai, 980-8575 Japan </aff>
        <aff id="Aff2"><label/>Molecular Hematology/Oncology, Tohoku University Graduate School, Sendai, Japan </aff>
        <aff id="Aff3"><label/>Department of Cell Proliferation, United Center for Advanced Research and Translational Medicine, Tohoku University Graduate School, Sendai, Japan </aff>
        <aff id="Aff4"><label/>Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan </aff>
        <aff id="Aff5"><label/>Department of Pediatrics, Tohoku University Graduate School, Sendai, Japan </aff>
        <aff id="Aff6"><label/>Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>4</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>30</day>
        <month>4</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2014</year>
      </pub-date>
      <volume>93</volume>
      <issue>9</issue>
      <fpage>1515</fpage>
      <lpage>1522</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>4</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2014</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Heterozygous <italic>GATA</italic>-<italic>2</italic> germline mutations are associated with overlapping clinical manifestations termed GATA-2 deficiency, characterized by immunodeficiency and predisposition to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, there is considerable clinical heterogeneity among patients, and the molecular basis for the evolution of immunodeficiency into MDS/AML remains unknown. Thus, we conducted whole-genome sequencing on a patient with a germline GATA-2 heterozygous mutation (c. 988 C &gt; T; p. R330X), who had a history suggestive of immunodeficiency and evolved into MDS/AML. Analysis was conducted with DNA samples from leukocytes for immunodeficiency, bone marrow mononuclear cells for MDS and bone marrow-derived mesenchymal stem cells. Whereas we did not identify a candidate genomic deletion that may contribute to the evolution into MDS, a total of 280 MDS-specific nonsynonymous single nucleotide variants were identified. By narrowing down with the single nucleotide polymorphism database, the functional missense database, and NCBI information, we finally identified three candidate mutations for <italic>EZH2</italic>, <italic>HECW2</italic> and <italic>GATA</italic>-<italic>1</italic>, which may contribute to the evolution of the disease.</p>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1007/s00277-014-2090-4) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>GATA-2</kwd>
        <kwd>GATA-2 deficiency</kwd>
        <kwd>MonoMAC</kwd>
        <kwd>Myelodysplastic syndrome</kwd>
        <kwd>Whole-genome sequencing</kwd>
        <kwd>EZH2</kwd>
        <kwd>GATA-1</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag Berlin Heidelberg 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>GATA-2 is a zinc finger transcription factor that plays crucial roles in hematopoiesis, as well as vascular, lymphatic, and neural development [<xref ref-type="bibr" rid="CR1">1</xref>]. Recently, heterozygous <italic>GATA</italic>-<italic>2</italic> germline mutations, both inherited and de novo, were reported to cause three overlapping clinical entities, characterized by a predisposition to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): (1) familial MDS/AML, (2) Emberger syndrome and (3) an immunodeficiency termed monocytopenia characterized by mycobacterium avium complex (MonoMAC)/dendritic cell, monocyte, B- and NK-lymphoid deficiency (DCML) [<xref ref-type="bibr" rid="CR2">2</xref>&#x2013;<xref ref-type="bibr" rid="CR4">4</xref>]. All these conditions are generally named &#x201C;GATA-2 deficiency&#x201D; syndrome.</p>
      <p>Nearly half of the individuals presenting with GATA-2 mutations will eventually develop MDS/AML, associated with fibrosis and megakaryocyte dysplasia. In contrast, many patients gradually develop DCML before MDS/AML, initially detected as mild chronic neutropenia, monocytopenia and/or NK deficiency [<xref ref-type="bibr" rid="CR2">2</xref>&#x2013;<xref ref-type="bibr" rid="CR4">4</xref>]. Therefore, there is considerable clinical heterogeneity among patients with GATA-2 deficiency, although all these conditions predominantly affect the hematologic and immune systems. In addition, the rate of evolution of the disease into MDS/AML appears to be rapid, with varying MDS and AML phenotypes and variable cytogenetic abnormalities [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Therefore, secondary genetic events may explain the clinical heterogeneity among cases of GATA-2 deficiency. In this regard, the most commonly associated cytogenetic finding is monosomy 7 and additional acquired mutations, such as those in <italic>ASXL1</italic> [<xref ref-type="bibr" rid="CR6">6</xref>]. However, the molecular basis for the evolution of GATA-2 deficiency into MDS/AML has not been elucidated, which affects our ability of early detection and treatment of the disease.</p>
      <p>Whole-genome sequencing has several advantages over candidate gene sequencing. It provides a comprehensive and nonbiased approach to mutation detection. More importantly, whole-genome paired-end sequencing is able to detect structural variants (SV; e.g., deletions, amplifications, inversions and translocations). Therefore, to investigate the genetic changes associated with the evolution of GATA-2 deficiency into MDS/AML, we performed whole-genome sequencing of MDS sample, which was compared with matched samples from nail, leukocyte at immunodeficiency, and bone marrow-derived mesenchymal stem cells (BM-MSCs).</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Patient and methods</title>
      <sec id="Sec3">
        <title>Study design and clinical samples</title>
        <p>All clinical samples were obtained from a single patient referred to our department for pancytopenia and emergence of myeloblasts in the peripheral blood. They included nails, peripheral leukocytes at immunodeficiency (MonoMAC), and bone marrow mononuclear cells for MDS (MDS). The patient signed an informed consent before sample collection, and all ethical considerations were followed according to the Declaration of Helsinki. This study was approved by the ethical committee of the Tohoku University Graduate School of Medicine.</p>
      </sec>
      <sec id="Sec4">
        <title>Cell culture</title>
        <p>Cells were grown in a humidified incubator at 37&#xA0;&#xB0;C with 5&#xA0;% carbon dioxide. Human K562 erythroleukemia cell lines were maintained in Roswell Park Memorial Institute (RPMI-1640) medium containing 10&#xA0;% fetal bovine serum (Biowest) and 1&#xA0;% penicillin&#x2013;streptomycin (Sigma). PLAT-GP Packaging Cell Lines (Cell Biolabs) was maintained in Dulbecco&#x2019;s modified Eagle medium (DMEM) containing 10&#xA0;% fetal bovine serum (Biowest) and 1&#xA0;% penicillin&#x2013;streptomycin (Sigma).</p>
      </sec>
      <sec id="Sec5">
        <title>Gene transfer and vectors</title>
        <p><italic>GATA</italic>-<italic>2</italic> mRNA was cloned into pBABE-puro vector (Addgene Plasmid 1764) [<xref ref-type="bibr" rid="CR7">7</xref>], and a single mutation was introduced with QuikChange Site-Directed Mutagenesis Kit (Agilent). The retroviral vector encoding human GATA-2 and the env (envelope glycoprotein) gene from the vesicular stomatitis virus (VSV-G) were co-transfected into PLAT-GP cells with FuGene HD (Promega). Seventy-two hours after transfection, the viral supernatant was used for infection. After spin infection into CD34-positive cells at 3,400&#xA0;rpm for 2&#xA0;h, the cells were cultured containing 1&#xA0;&#x3BC;g/mL Puromycin (Sigma) for the selection of the transduced cells.</p>
      </sec>
      <sec id="Sec6">
        <title>Quantitative ChIP analysis</title>
        <p>Real-time-PCR-based quantitative chromatin immunoprecipitation (ChIP) analysis was conducted essentially as described [<xref ref-type="bibr" rid="CR8">8</xref>]. Cells were crosslinked with 1&#xA0;% formaldehyde for 10&#xA0;min at room temperature. The nuclei lysate was sonicated to reduce DNA length using Sonifier (Branson). The protein-DNA complexes were immunoprecipitated by specific antibody and Protein A Sepharose (Sigma). Immunoprecipitated DNA fragments were quantified by real-time PCR to amplify regions of 75&#x2013;150&#xA0;bp overlapping with the appropriate motif. Product was measured by SYBR Green fluorescence in 20-&#x3BC;L reactions, and the amount of product was determined relative to a standard curve generated from titration of input chromatin. Analysis of post-amplification dissociation curves showed that primer pairs generated single products.</p>
      </sec>
      <sec id="Sec7">
        <title>Primers</title>
        <p>Primers used in the study were listed in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Oligonucleotide primers</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Designation</th><th>Forward and reverse sequences(5&#x2032;-3&#x2032;)</th></tr></thead><tbody><tr><td colspan="2">Primers used for GATA-2 sequencing</td></tr><tr><td rowspan="2">&#x2003;
<italic>GATA</italic>-<italic>2</italic> exon 2</td><td>GTTTTGAGCCTTGGGCTTT</td></tr><tr><td>CAATTTTTCAGCAGCTCGATT</td></tr><tr><td rowspan="2">&#x2003;
<italic>GATA</italic>-<italic>2</italic> exon 3</td><td>GGAGTCGTGATCTCAATGTCTG</td></tr><tr><td>ATCTGCTGGGGGCTATTAGAG</td></tr><tr><td rowspan="2">&#x2003;
<italic>GATA</italic>-<italic>2</italic> exon 4</td><td>ACTCCCTCCCGAGAACTTG</td></tr><tr><td>CGTCTGCATTTGAAGGAGTTT</td></tr><tr><td rowspan="2">&#x2003;
<italic>GATA</italic>-<italic>2</italic> exon 5</td><td>GAGATTTAGCCCTCCTTGACTG</td></tr><tr><td>AGCACAAAGCGCAGAGGT</td></tr><tr><td rowspan="2">&#x2003;
<italic>GATA</italic>-<italic>2</italic> exon 6</td><td>GAAGGTCGGGCACAATTC</td></tr><tr><td>ACAGGTGCCATGTGTCCA</td></tr><tr><td colspan="2">Primers used for validation sequencing</td></tr><tr><td rowspan="2">&#x2003;
<italic>EZH2</italic>
</td><td>CATCAAAAGTAACACATGGAAACC</td></tr><tr><td>GCTGCTTTAAAACATAATTCCACA</td></tr><tr><td rowspan="2">&#x2003;
<italic>HECW2</italic>
</td><td>GTCCATATCCTACCTCCAGTAGC</td></tr><tr><td>GACAGCTCCTGCAATGAGAGT</td></tr><tr><td rowspan="2">&#x2003;
<italic>GATA</italic>-<italic>1</italic>
</td><td>TAGACCTTGGGCAGCTCCT</td></tr><tr><td>CCTTGGTAGAGATGGGCAGTA</td></tr><tr><td colspan="2">Primers used for quantitative ChIP</td></tr><tr><td rowspan="2">&#x2003;
<italic>GATA</italic>-<italic>2</italic> &#x2212;2.4&#xA0;kb</td><td>GTGGAGCTCTAGGGTACCATTT</td></tr><tr><td>TGAGGACACCTCATTAGAGCAG</td></tr><tr><td rowspan="2">&#x2003;
<italic>GATA</italic>-<italic>2</italic> &#x2212;3.5&#xA0;kb</td><td>GTCCGGGGTAATTTTTCATCT</td></tr><tr><td>GCAGATAACGACTGGCTATTCA</td></tr><tr><td rowspan="2">&#x2003;
<italic>GATA</italic>-<italic>2</italic> &#x2212;4.6&#xA0;kb</td><td>GAGATGAGCTAATCCCGCCGTA</td></tr><tr><td>AAGGCTGTATTTTTCCAGGCT</td></tr><tr><td rowspan="2">&#x2003;
<italic>NECDIN</italic> promoter</td><td>GAAGAGCTCCTGGACGCAGA</td></tr><tr><td>TGCAAAGTTAGGGTCGCTCAG</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec8">
        <title>Western blot analysis</title>
        <p>Whole cell extracts were prepared by boiling cells for 10&#xA0;min in SDS sample buffer [25&#xA0;mM Tris (pH&#xA0;6.8), 2&#xA0;% &#x3B2;-mercaptoethanol, 3&#xA0;% SDS, 0.1&#xA0;% bromophenol blue, 5&#xA0;% glycerol] at 1&#x2009;&#xD7;&#x2009;10<sup>7</sup> cells/mL. Extracts from 1 to 2&#x2009;&#xD7;&#x2009;10<sup>5</sup> cells were resolved by SDS-PAGE and transferred to Hybond-P (GE Healthcare). The proteins were measured by semi-quantitatively with ECL-Plus (GE Healthcare) and CL-X Posure<sup>TM</sup> Film (Thermo Scientific).</p>
      </sec>
      <sec id="Sec9">
        <title>Antibodies</title>
        <p>Antibodies to GATA-2 (H-116) and Actin (I-19) were obtained from Santa Cruz Biotechnology. Control rabbit IgG was obtained from Abcam. Phycoerythrin (PE)-labeled human CD29, PE-labeled human CD34, fluorescein isothiocyanate (FITC)-labeled mouse/human CD44, FITC-labeled human CD45, FITC-labeled human CD90 antibodies were purchased from BD Biosciences.</p>
        <p>The anti-GATA-2 antibody (H-116) recognizes amino acid residues 120&#x2013;235 of human GATA-2.</p>
      </sec>
      <sec id="Sec10">
        <title>Flow cytometry (FACS)</title>
        <p>The cells collected from culture were washed twice with phosphate-buffered saline (PBS; Sigma). The cells were then incubated with PE- and FITC-labeled antibodies, washed twice with PBS, and analyzed using FACSAria II (Beckton, Dickinson). The collected data were processed with FlowJo software (<ext-link ext-link-type="uri" xlink:href="http://www.flowjo.com/">http://www.flowjo.com/</ext-link>).</p>
      </sec>
      <sec id="Sec11">
        <title>Establishment of BM-MSCs</title>
        <p>To establish BM-MSCs, bone marrow mononuclear cells from the patient were cultured in DMEM (Life Technologies) supplemented with 20&#xA0;% fetal bovine serum (Life Technologies), 10&#xA0;ng/mL basic fibroblast growth factor (PeproTech), 10&#xA0;mM HEPES (Life Technologies), and 100&#xA0;&#x3BC;g/mL penicillin/streptomycin, as previously described [<xref ref-type="bibr" rid="CR9">9</xref>]. To induce differentiation into osteroblasts and adipocytes, the hMSC Mesenchymal Stem Cell Differentiation Medium (Lonza) for osteogenic and adipogenic, respectively, was used. Osteogenic cell layers were positive for Alkaline Phosphatase staining, and typical adipocytes contained oil drops that were stained with Oil Red O.</p>
      </sec>
      <sec id="Sec12">
        <title>Genome analysis</title>
        <p>To identify MDS-specific genome alterations, whole-genome sequencing was conducted on MonoMAC, MDS and BM-MSCs (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Genomic DNA was extracted with the DNeasy Blood &amp; Tissue Kit (QIAGEN) or ISOHAIR (NIPPON GENE). For whole-genome sequencing, the DNA samples were amplified with the REPLI-g Midi Kit (QIAGEN). Sequencing libraries were prepared from 1&#xA0;&#x3BC;g of the amplified DNA according to the TruSeq DNA Sample Prep Guide (Illumina). The libraries were sequenced on an Illumina HiSeq 2000 with HiSeq control software (HCS) version 1.5 and Real-Time Analysis (RTA) software version 1.13. After sequencing, reads were mapped to the human reference genome (GRCh37/hg19) with decoy sequences (hs37d5) using BWA [<xref ref-type="bibr" rid="CR10">10</xref>] with the default options. Then, variant calling was conducted using the GATK Unified Genotyper [<xref ref-type="bibr" rid="CR11">11</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Study design. Whole-genome sequencing conducted with MonoMAC, MDS and BM-MSCs samples to identify MDS-specific genome alterations. Sanger sequence-based validation analysis was conducted on all samples, including a nail sample</p></caption><graphic xlink:href="277_2014_2090_Fig1_HTML" id="MO1"/></fig></p>
        <p>Sanger sequence-based validation analysis was conducted with all samples, including the nail sample, using an ABI 3730xl DNA analyzer and the ABI BigDye Terminator Cycle Sequencing Kit (Applied Biosystems). The validation analyses were conducted based on the DNA samples without amplification.</p>
      </sec>
    </sec>
    <sec id="Sec13" sec-type="results">
      <title>Results and discussion</title>
      <sec id="Sec14">
        <title>Case report</title>
        <p>In September 2010, a 35-year-old man was referred to our department due to pancytopenia and emergence of myeloblasts in the peripheral blood. Peripheral blood count revealed a white blood cell count of 1.2&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L, with 79&#xA0;% neutrophils, 16&#xA0;% lymphocytes, 1&#xA0;% eosinophils, 1&#xA0;% atypical lymphocytes, and 3&#xA0;% myeloblasts. The hemoglobin level was 9.8&#xA0;g/dl, and the platelet count was 27&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L. Bone marrow analysis indicated a total nucleated cell count of 2.2&#x2009;&#xD7;&#x2009;10<sup>10</sup>/L, with dysplastic morphological changes in all lineages. The bone marrow contained 11&#xA0;% leukemic blasts, all positive for CD7, CD13, CD33, CD34, and HLA-DR. Cytogenetic analysis indicated the presence of trisomy 8. The patient was diagnosed with MDS, classified into the refractory anemia with excess blasts (RAEB-2), and had &#x201C;Very high&#x201D; risk according to the criteria of revised international prognostic index (IPSS-R) [<xref ref-type="bibr" rid="CR12">12</xref>]. In January 2011, the case rapidly developed into AML, and received hematopoietic stem cell transplantation from a matched unrelated donor with reduced intensity conditioning regimen.</p>
        <p>Since the age of 16&#xA0;years, he had been treated for nontuberculous mycobacterial infection, cryptococcal meningitis and recurrent cutaneous human papilloma virus infection. For this reason, he was initially diagnosed with primary immunodeficiency. There was no family history of increased susceptibility to infection, or onset of MDS/AML. Based on our clinical findings and the family history, we suspected that the patient might have sporadic MonoMAC syndrome.</p>
      </sec>
      <sec id="Sec15">
        <title>Identification of a germline GATA-2 mutation</title>
        <p>Sanger sequencing for <italic>GATA</italic>-<italic>2</italic> cDNA revealed a 988 C &gt; T heterozygous mutation (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>). We confirmed that the mutation was germline because it involved the nail sample (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>). This mutation resulted in the generation of a premature stop codon at Arg330, located in the N-terminal zinc finger domain (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>). As GATA-2 DNA binding activity is mediated through the C-terminal zinc finger domain [<xref ref-type="bibr" rid="CR1">1</xref>], the mutated GATA-2 is predicted to be defective in DNA binding. To test the hypothesis, we overexpressed wild-type or mutated (R330X) GATA-2 in K562 cells (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2b</xref>). Quantitative ChIP analysis was conducted with anti-GATA-2 antibody at endogenous loci (GATA-2 &#x2212;4.6, &#x2212;3.5 and &#x2212;2.4&#xA0;kb), which were selected from GATA-2 ChIP-seq analysis based on K562 cells [<xref ref-type="bibr" rid="CR8">8</xref>]. As shown in Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref>, GATA-2 chromatin occupancy was obviously increased by overexpression of wild-type GATA-2. However, although the antibody could recognize GATA-2 330X (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2b</xref>), the levels of GATA-2 chromatin occupancy in GATA-2 R330X-overexpressing K562 cells were similar to the control cells. Thus, we consider that the heterozygous GATA-2 R330X mutation is a loss-of-function mutation.<fig id="Fig2"><label>Fig. 2</label><caption><p>Identification of a germline heterozygous GATA-2 mutation. <bold>a</bold> Heterozygous germline GATA-2 mutation was confirmed with the nail, BM-MSC, MonoMAC and MDS samples: <italic>GATA</italic>-<italic>2</italic> c. 988 C &gt; T, p. R330X. ZF, zinc finger. Numbering relative to adenine in the ATG start codon of <italic>GATA</italic>-<italic>2</italic> (GenBank NM_001145661.1) and the first methionine (GenBank NP_116027.2) [<xref ref-type="bibr" rid="CR3">3</xref>]. <bold>b</bold> Western blot analysis to detect wild-type and mutated GATA-2 in K562 cells. Actin was used as a loading control. GATA-2 R330X was detected by the anti-GATA-2 antibody (H-116), as it recognizes amino acid residues 120&#x2013;235 of human GATA-2. Asterisk, cross-reactive band. <bold>c</bold> Quantitative ChIP analysis to examine GATA-2 occupancy in wild-type and mutated GATA-2-overexpressing K562 cells (<italic>n</italic>&#x2009;=&#x2009;3, mean&#x2009;&#xB1;&#x2009;SD). <italic>NECDIN</italic> promoter was included as a negative control</p></caption><graphic xlink:href="277_2014_2090_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec16">
        <title>Generation and characterization of BM-MSCs</title>
        <p>We established BM-MSCs from BM mononuclear cells from the patient, and used for the reference control for whole-genome analysis. Immunophenotypic analysis confirmed that the BM-MSCs expressed typical markers, i.e., CD29, CD44, CD90, and CD105, but not CD14, CD34, and CD45 (Supplementary Fig.&#xA0;<xref rid="MOESM1" ref-type="media">1a</xref>) [<xref ref-type="bibr" rid="CR13">13</xref>]. Furthermore, the established BM-MSCs had the capacity to differentiate into adipocytes and osteoblasts (Supplementary Fig.&#xA0;<xref rid="MOESM1" ref-type="media">1b</xref>). Sanger sequencing also confirmed that the cells harbored the identical <italic>GATA</italic>-<italic>2</italic> mutation (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>).</p>
      </sec>
      <sec id="Sec17">
        <title>Whole-genome sequencing identified mutations in EZH2, HECW2, and GATA-1</title>
        <p>To elucidate the secondary genetic changes associated with the evolution to MDS/AML, we performed whole-genome sequencing with DNA samples from nail, MonoMAC, MDS, and BM-MSCs (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). However, the data from the nail sample were excluded from the analysis due to a low mapping rate of the sequence on the human genome.</p>
        <p>First, we focused on the MDS-specific genome deletion. GATA-2 plays a crucial role in the proliferation of hematopoietic stem cells (HSCs) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Thus, it is possible that <italic>GATA</italic>-<italic>2</italic> haploinsufficient HSCs could have a reduced proliferative activity. Therefore, secondary deletions involving oncogenic genes, such as a tumor suppressor gene, may promote the evolution to MDS/AML. In support of this hypothesis, a recent study revealed that a heterozygous 3-kb deletion, removing exons 7&#x2013;9 of <italic>TP53</italic> gene, was associated with the onset of therapy-related AML through whole-genome sequencing [<xref ref-type="bibr" rid="CR15">15</xref>]. To identify the MDS-specific gene deletion, we used several SV callers, including BreakDancer, Pindel, and CNVnator, as described previously [<xref ref-type="bibr" rid="CR16">16</xref>]. However, we failed to identify the candidate genomic deletion that may contribute to the evolution into MDS.</p>
        <p>Our next strategy was to sort out the point mutations, using the GATK Unified Genotyper [<xref ref-type="bibr" rid="CR11">11</xref>]. They were observed in the MDS sample, but not in MonoMAC or BM-MSCs. A total of 280 MDS-specific nonsynonymous single nucleotide variants (nsSNVs) were identified, which were subsequently narrowed down based on the single nucleotide polymorphism (SNP) database, the functional missense database and NCBI information (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/">http://www.ncbi.nlm.nih.gov</ext-link>; Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). Finally, we identified three candidate mutations, namely EZH2 (Enhancer of zeste homolog 2, Drosophila), HECW2 (HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2), and GATA-1 (GATA-binding protein 1; Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>, Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). Sanger sequence-based validation analysis confirmed that all three mutations were observed only in the MDS sample (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). As expected, the peak height of the mutated signal was lower than that of the wild-type signal, presumably reflecting the frequency of leukemic blasts (11&#xA0;%).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Point mutations identified in MDS sample</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="9">Functional missense database</th></tr><tr><th>Name</th><th>Chr.</th><th>Depth</th><th>SIFT</th><th>PolyPhen2</th><th>LJB_PhyloP</th><th>LJB MutationTaster</th><th>LJB_LRT</th><th>AA Change</th></tr></thead><tbody><tr><td>EZH2</td><td char="." align="char">7</td><td char="." align="char">49</td><td char="." align="char">0.06</td><td char="." align="char">0.926</td><td char="." align="char">0.9839</td><td char="." align="char">0.9995</td><td char="." align="char">1.0</td><td>E210K</td></tr><tr><td>HECW2</td><td char="." align="char">2</td><td char="." align="char">61</td><td char="." align="char">0.06</td><td char="." align="char">0.002</td><td char="." align="char">0.03258</td><td char="." align="char">0.005</td><td char="." align="char">0.0318</td><td>V701M</td></tr><tr><td>GATA-1</td><td char="." align="char">X</td><td char="." align="char">21</td><td char="." align="char">0</td><td char="." align="char">0.944</td><td char="." align="char">0.99824</td><td char="." align="char">0.9999</td><td char="." align="char">1.0</td><td>R293Q</td></tr></tbody></table><table-wrap-foot><p>Three mutations were not identified in SNP database (dbSNP130 and 1000G_ALL)</p><p>
<italic>Chr</italic> chromosome, <italic>SIFT</italic> sorting intolerant from tolerant, <italic>PolyPhen2</italic> polymorphism phenotyping v2, <italic>LJB_PhyloP</italic> pathogenicity score from dbNSFP, <italic>LJB_MutationTaster</italic> pathogenicity probability score from dbNSFP, <italic>LJB_LRT</italic> pathogenicity probability score from dbNSFP, <italic>AA</italic> amino acid.</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig. 3</label><caption><p>Validation analysis for MDS-specific point mutations. Validation analysis of the MDS-specific point mutations. Sanger sequence conducted to validate point mutations identified by whole-genome sequencing. For the <italic>HECW2</italic> mutation, the nucleotide substitution was described as opposite strand (G &gt; A to C &gt; T)</p></caption><graphic xlink:href="277_2014_2090_Fig3_HTML" id="MO3"/></fig></p>
        <p>EZH2 is a member of the Polycomb group, which is involved in the maintenance of the transcriptional repressive state of genes by trimethylation of histone H3 at lysine 27 [<xref ref-type="bibr" rid="CR17">17</xref>]. It is well established that EZH2 loss-of-function mutations are frequently identified in MDS [<xref ref-type="bibr" rid="CR18">18</xref>]. Amino acid position at 210 (Glu) is located at SWI3-ADA2-N-CoR-TFIIIB (SANT) domain that has been shown to interact both with histone tails and with other proteins [<xref ref-type="bibr" rid="CR19">19</xref>]. Whereas gain-of-function mutations of EZH2 have also been attributable to pathogenesis of lymphoma, the mutations were observed at the C-terminal catalytic SET domain (Y641 and Y677) [<xref ref-type="bibr" rid="CR20">20</xref>]. Thus, we assume that the EZH2 E210K mutation could be loss-of-function mutation. HECW2 is predicted to be ubiquitin ligase that degrades ATR (ataxia-telangiectasia-mutated-and-Rad3-related) kinase [<xref ref-type="bibr" rid="CR21">21</xref>]. However, its role in hematopoiesis is unknown. Finally, GATA-1 is a member of the GATA transcription factors promoting erythrocyte, megakaryocyte, mast cell, and eosinophil development [<xref ref-type="bibr" rid="CR1">1</xref>]. Amino acid position at 293 (Arg) is located in the C-terminal zinc finger domain, which is important for the recognition of the (A/T)GATA(A/G) motif, and to confer its transcriptional activity [<xref ref-type="bibr" rid="CR1">1</xref>]. Noticeably, a recent report suggests that defective GATA-1 function results in the dyserythropoiesis, which is characteristic of MDS [<xref ref-type="bibr" rid="CR22">22</xref>]. Based on the functional missense database, the mutations of both E210K on EZH2 and R293Q on GATA-1 may have significant effect on their endogenous functions (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). In support of the hypothesis, mutation frequencies for EZH2 (38.8&#xA0;%) and GATA-1 (38.1&#xA0;%) were higher than HECW2 (24.6&#xA0;%; Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Thus, at least two secondary mutations in EZH2 and GATA-1 may have contributed to the early stage of clonal evolution into MDS in the present case. Future investigations are needed to determine the possible involvement of HECW2 mutation.<fig id="Fig4"><label>Fig. 4</label><caption><p>Quantification of the mutation load for EZH2, GATA-1 and HECW2. Percentage of the mutated reads per the total number of reads (both wild-type and mutated) in MDS sample was calculated for GATA-2 (c. 988 C &gt; T), EZH2 (c. 628 G &gt; A), GATA-1 (c. 878 G &gt; A) and HECW2 (c. 2101 G &gt; A)</p></caption><graphic xlink:href="277_2014_2090_Fig4_HTML" id="MO4"/></fig></p>
        <p>In conclusion, we conducted whole-genome sequencing with samples from a patient with germline GATA-2 mutation evolving immunodeficiency and MDS/AML. The new mutations we identified in <italic>EZH2</italic>, <italic>HECW2</italic> and <italic>GATA</italic>-<italic>1</italic> appear to be important secondary events leading to the development of MDS/AML of this patient.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <sec id="Sec18">
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="277_2014_2090_MOESM1_ESM.eps">
            <label>Supplementary Fig. 1</label>
            <caption>
              <p>Phenotyping of the patient-derived BM-MSCs. <bold>a</bold> Human BM-MSCs expressed cell-surface antigens, characteristic of BM-MSCs. <bold>b</bold> Differentiation of the BM-MSCs. Osteogenic cell layer was positive for alkaline phosphatase staining. Typical adipocytes contained oil drops that were stained with Oil Red O (EPS 5107&#xA0;kb)</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material id="Fig5" content-type="local-data">
          <media id="MO5" xlink:href="277_2014_2090_Fig5_ESM.gif">
            <caption>
              <p>High Resulotion image (GIF 254&#xA0;kb)</p>
            </caption>
          </media>
        </supplementary-material>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank Drs. Mamoru Takahashi, Riu Yamashita, Kengo Kinoshita, and Kazuhiko Igarashi (Tohoku University) for their helpful discussions. We acknowledge the members of the Biomedical Research Core of Tohoku University School of Medicine and Biomedical Research Unit of Tohoku University Hospital for their support. Drs. Fujiwara and Harigae have received a research grant from Chugai Pharmaceutical Co., Ltd.</p>
      <sec id="d30e1133">
        <title>Conflict of interest</title>
        <p>All authors declared no conflict of interest.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bresnick</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Keles</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>GATA switches as developmental drivers</article-title>
          <source>J Biol Chem</source>
          <year>2010</year>
          <volume>285</volume>
          <fpage>31087</fpage>
          <lpage>31093</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.R110.159079</pub-id>
          <pub-id pub-id-type="pmid">20670937</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dickinson</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bigley</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Reynard</surname>
              <given-names>LN</given-names>
            </name>
            <name>
              <surname>Hussain</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Haniffa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lakey</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Rahman</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>XN</given-names>
            </name>
            <name>
              <surname>McGovern</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Pagan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cookson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chua</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Wallis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cant</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Keavney</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Chinnery</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Loughlin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hambleton</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Santibanez-Koref</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Collin</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>118</volume>
          <fpage>2656</fpage>
          <lpage>2658</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2011-06-360313</pub-id>
          <pub-id pub-id-type="pmid">21765025</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hsu</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Sampaio</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Calvo</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Lemieux</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Frucht</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Vinh</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Auth</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Olivier</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Uzel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zerbe</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Spalding</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pittaluga</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Raffeld</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kuhns</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Paulson</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Marciano</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Gea-Banacloche</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Orange</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Cuellar-Rodriguez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hickstein</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Holland</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>118</volume>
          <fpage>2653</fpage>
          <lpage>2655</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2011-05-356352</pub-id>
          <pub-id pub-id-type="pmid">21670465</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ostergaard</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Connell</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Steward</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Brice</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Woollard</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Dafou</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kilo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Smithson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lunt</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Murday</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Hodgson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Keenan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pilz</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Martinez-Corral</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Makinen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mortimer</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Jeffery</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Trembath</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Mansour</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)</article-title>
          <source>Nat Genet</source>
          <year>2011</year>
          <volume>43</volume>
          <fpage>929</fpage>
          <lpage>931</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.923</pub-id>
          <pub-id pub-id-type="pmid">21892158</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hahn</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Chong</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Carmichael</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Wilkins</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Brautigan</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>XC</given-names>
            </name>
            <name>
              <surname>Babic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carmagnac</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Kok</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Gagliardi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Friend</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Ekert</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Butcher</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>ID</given-names>
            </name>
            <name>
              <surname>To</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Timms</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Storek</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Altree</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Escher</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bardy</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Suthers</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>D'Andrea</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Horwitz</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>HS</given-names>
            </name>
          </person-group>
          <article-title>Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia</article-title>
          <source>Nat Genet</source>
          <year>2011</year>
          <volume>43</volume>
          <fpage>1012</fpage>
          <lpage>1017</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.913</pub-id>
          <pub-id pub-id-type="pmid">21892162</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>B&#xF6;d&#xF6;r</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Renneville</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Charazac</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Iqbal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Etancelin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cavenagh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Barnett</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Kramarzov&#xE1;</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Krishnan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Matolcsy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Preudhomme</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fitzgibbon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Owen</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival</article-title>
          <source>Haematologica</source>
          <year>2012</year>
          <volume>97</volume>
          <fpage>890</fpage>
          <lpage>894</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.2011.054361</pub-id>
          <pub-id pub-id-type="pmid">22271902</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morgenstern</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Land</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line</article-title>
          <source>Nucleic Acids Res</source>
          <year>1990</year>
          <volume>18</volume>
          <fpage>3587</fpage>
          <lpage>3596</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/18.12.3587</pub-id>
          <pub-id pub-id-type="pmid">2194165</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujiwara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>O'Geen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Keles</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Blahnik</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>YA</given-names>
            </name>
            <name>
              <surname>Harigae</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Farnham</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Bresnick</surname>
              <given-names>EH</given-names>
            </name>
          </person-group>
          <article-title>Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy</article-title>
          <source>Mol Cell</source>
          <year>2009</year>
          <volume>36</volume>
          <fpage>667</fpage>
          <lpage>681</lpage>
          <pub-id pub-id-type="doi">10.1016/j.molcel.2009.11.001</pub-id>
          <pub-id pub-id-type="pmid">19941826</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Solchaga</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Penick</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Porter</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Goldberg</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Caplan</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Welter</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>FGF-2 enhances the mitotic and chondrogenic potentials of human adult bone marrow-derived mesenchymal stem cells</article-title>
          <source>J Cell Physiol</source>
          <year>2005</year>
          <volume>203</volume>
          <fpage>398</fpage>
          <lpage>409</lpage>
          <pub-id pub-id-type="doi">10.1002/jcp.20238</pub-id>
          <pub-id pub-id-type="pmid">15521064</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Durbin</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title>
          <source>Bioinformatics</source>
          <year>2009</year>
          <volume>25</volume>
          <fpage>1754</fpage>
          <lpage>1760</lpage>
          <pub-id pub-id-type="doi">10.1093/bioinformatics/btp324</pub-id>
          <pub-id pub-id-type="pmid">19451168</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McKenna</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hanna</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Banks</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sivachenko</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cibulskis</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kernytsky</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Garimella</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Altshuler</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gabriel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Daly</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>DePristo</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title>
          <source>Genome Res</source>
          <year>2010</year>
          <volume>20</volume>
          <fpage>1297</fpage>
          <lpage>1303</lpage>
          <pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id>
          <pub-id pub-id-type="pmid">20644199</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greenberg</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Tuechler</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Schanz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sanz</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Garcia-Manero</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sol&#xE9;</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Bowen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Fenaux</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dreyfus</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kantarjian</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kuendgen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Levis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Malcovati</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cazzola</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cermak</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fonatsch</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Le Beau</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Slovak</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Krieger</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Luebbert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maciejewski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Magalhaes</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Miyazaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Pfeilst&#xF6;cker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sekeres</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sperr</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Stauder</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tauro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Valent</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Vallespi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>van de Loosdrecht</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Germing</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Haase</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Revised international prognostic scoring system for myelodysplastic syndromes</article-title>
          <source>Blood</source>
          <year>2012</year>
          <volume>120</volume>
          <fpage>2454</fpage>
          <lpage>2465</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2012-03-420489</pub-id>
          <pub-id pub-id-type="pmid">22740453</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pittenger</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Mackay</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Jaiswal</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Douglas</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mosca</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Moorman</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Simonetti</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Craig</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Marshak</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Multilineage potential of adult human mesenchymal stem cells</article-title>
          <source>Science</source>
          <year>1999</year>
          <volume>284</volume>
          <fpage>143</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="doi">10.1126/science.284.5411.143</pub-id>
          <pub-id pub-id-type="pmid">10102814</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>FY</given-names>
            </name>
            <name>
              <surname>Orkin</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation</article-title>
          <source>Blood</source>
          <year>1997</year>
          <volume>89</volume>
          <fpage>3636</fpage>
          <lpage>3643</lpage>
          <pub-id pub-id-type="pmid">9160668</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Link</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Schuettpelz</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Walter</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Kulkarni</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Payton</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Ivanovich</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Goodfellow</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Le Beau</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Koboldt</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Dooling</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Fulton</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Bender</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Fulton</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Delehaunty</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Fronick</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Appelbaum</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Abbott</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>O'Laughlin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>McLellan</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Varghese</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nagarajan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Heath</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Graubert</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ley</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Zambetti</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Mardis</surname>
              <given-names>ER</given-names>
            </name>
          </person-group>
          <article-title>Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML</article-title>
          <source>JAMA</source>
          <year>2011</year>
          <volume>305</volume>
          <fpage>1568</fpage>
          <lpage>1576</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.2011.473</pub-id>
          <pub-id pub-id-type="pmid">21505135</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suzuki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yasuda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shiraishi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Miyano</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nagasaki</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>ClipCrop: a tool for detecting structural variations with single-base resolution using soft-clipping information</article-title>
          <source>BMC Bioinformatics</source>
          <year>2011</year>
          <volume>12</volume>
          <issue>Suppl 14</issue>
          <fpage>S7</fpage>
          <pub-id pub-id-type="doi">10.1186/1471-2105-12-S14-S7</pub-id>
          <pub-id pub-id-type="pmid">22373054</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>M&#xFC;ller</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Vargas</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Sengupta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wild</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>O'Connor</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Kingston</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Histone methyltransferase activity of a Drosophila Polycomb group repressor complex</article-title>
          <source>Cell</source>
          <year>2002</year>
          <volume>111</volume>
          <fpage>197</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(02)00976-5</pub-id>
          <pub-id pub-id-type="pmid">12408864</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cazzola</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Della Porta</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Malcovati</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>The genetic basis of myelodysplasia and its clinical relevance</article-title>
          <source>Blood</source>
          <year>2013</year>
          <volume>122</volume>
          <fpage>4021</fpage>
          <lpage>4034</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2013-09-381665</pub-id>
          <pub-id pub-id-type="pmid">24136165</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ishizuka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Guenther</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Lazar</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>A SANT motif in the SMRT corepressor interprets the histone code and promotes histone deacetylation</article-title>
          <source>EMBO J</source>
          <year>2003</year>
          <volume>22</volume>
          <fpage>3403</fpage>
          <lpage>3410</lpage>
          <pub-id pub-id-type="doi">10.1093/emboj/cdg326</pub-id>
          <pub-id pub-id-type="pmid">12840002</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCabe</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Ott</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Ganji</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Korenchuk</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Van Aller</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Graves</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Della Pietra</surname>
              <given-names>A</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Diaz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>LaFrance</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Mellinger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Duquenne</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Kruger</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>McHugh</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Brandt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Dhanak</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Tummino</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Creasy</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations</article-title>
          <source>Nature</source>
          <year>2012</year>
          <volume>492</volume>
          <fpage>108</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="doi">10.1038/nature11606</pub-id>
          <pub-id pub-id-type="pmid">23051747</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muralikrishna</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Chaturvedi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sinha</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Parnaik</surname>
              <given-names>VK</given-names>
            </name>
          </person-group>
          <article-title>Lamin misexpression upregulates three distinct ubiquitin ligase systems that degrade ATR kinase in HeLa cells</article-title>
          <source>Mol Cell Biochem</source>
          <year>2012</year>
          <volume>365</volume>
          <fpage>323</fpage>
          <lpage>332</lpage>
          <pub-id pub-id-type="doi">10.1007/s11010-012-1272-4</pub-id>
          <pub-id pub-id-type="pmid">22382637</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frisan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Vandekerckhove</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>de Thonel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pierre-Eug&#xE8;ne</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sternberg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arlet</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Floquet</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gyan</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kosmider</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Dreyfus</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gabet</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Courtois</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vyas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ribeil</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Zermati</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lacombe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mayeux</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Solary</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Garrido</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hermine</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Fontenay</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes</article-title>
          <source>Blood</source>
          <year>2012</year>
          <volume>119</volume>
          <fpage>1532</fpage>
          <lpage>1542</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2011-03-343475</pub-id>
          <pub-id pub-id-type="pmid">22160620</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
